Alex Zhavoronkov, Insilico CEO
With a new $255M megaround in hand, Alex Zhavoronkov has big plans for Insilico. Are they feasible?
If you take Alex Zhavoronkov at his word, it won’t be long until he rules over biotech’s AI drug discovery arena from atop his perch as Insilico CEO.
On the heels of a megaround announced Tuesday morning, the media-savvy exec outlined a vision of the not-so-distant future where AI-focused companies crash and burn akin to the dot-com bubble in the early 2000s. Zhavoronkov likened the current environment to 1998, when there was a glut of biotechs that soaked up capital but proved unable to deliver on their promises, he opined to Endpoints News.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
